Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY: BMY )

58.04 -0.10 (-0.17%)
Official Closing Price Updated: 7:00 PM EDT, Sep 29, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Bristol-Myers Squibb

< Previous 1 2
...
25 26 27 28 29 30 31 32 Next >
The Daily Biotech Pulse: Merck Rallies On Antiviral Pill Data, Gilead Files For Yescarta Label Expansion, Exscientia IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA Calendar Scaling The Peaks (Biotech Stocks... 
Via Benzinga
Exposures Product Safety
Merck Puts Up $11.5 Billion In Acceleron Deal As It Expands Its Cancer Dominance
Merck will buy a company focused, partly, on blood cancer treatment. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Merck Seals Acceleron Pharma Deal For $180/Share: Highlights
Putting all the speculations at bay, Merck & Co Inc (NYSE: MRK) has agreed to acquire Acceleron Pharma Inc (NASDAQ: XLRN) for $180 per share in cash... 
Via Benzinga
A Bit Of A Recovery
While Germany remains without a government, Japan has a new prime minister who will lead his party in the election this week. 
Via Talk Markets
These 3 Top Healthcare Stocks Are Screaming Buys Right Now
If the market crashes these companies could be insulated. 
Via The Motley Fool
AstraZeneca's Saphnelo For Lupus Treatment Approved In Japan
The Japanese Ministry of Health, Labor and Welfare (MHLW) has approved AstraZeneca plc’s (NASDAQ: AZN) Saphnelo (anifrolumab) for systemic lupus... 
Via Benzinga
Merck Reportedly Lead Bidder In $11B Acceleron Buyout: WSJ
The Wall Street Journal reported that Merck & Co Inc (NYSE: MRK) is in advanced talks to acquire Acceleron Pharma Inc (NASDAQ: XLRN), citing... 
Via Benzinga
Acceleron Stock Heats Up On $11 Billion Takeover Rumor; So, Who's The Buyer?
A biotech working in lung and blood diseases, as well as cancer, could be acquired. 
Via Investor's Business Daily
Bristol Myers' Two Opdivo Based Regimes Under FDA Review For Esophageal Cancer
The FDA has accepted for review Bristol Myers Squibb & Co Inc's (NYSE: BMY) supplemental marketing applications seeking approval for two Opdivo (nivolumab... 
Via Benzinga
Exposures Product Safety
Acceleron In Advanced $11B Buyout Talks: Bloomberg
Frothy rumors about possible M&A discussions at Acceleron Pharma Inc (NASDAQ: XLRN) were capped with a Bloomberg report asserting that the Company is... 
Via Benzinga
Bristol Myers: Worries Create Opportunity
Bristol Myers Squibb Company sells at a low valuation due to worries over patent expirations. However, the company is working to replace the eventual revenue losses by developing its robust product... 
Via Talk Markets
Topics Intellectual Property
Exposures Intellectual Property
Is Bristol Myers Squibb Stock a Buy?
Maybe, but not if you're looking for major growth over the short term. 
Via The Motley Fool
89 Firms going Ex-Dividend next week, including Philip Morris, Cardinal Health and Nutrien
Several well-known large-cap stocks going ex-dividend next week 
Via Talk Markets
Why Acceleron Pharma Stock Jumped This Week
Buyout rumors are swirling around this mid-cap biotech company. 
Via The Motley Fool
3 Cheap Healthcare Stocks to Buy Right Now
The COVID-19 pandemic brought a renewed interest into the healthcare sector, and with the surging Delta variant raging across the country, that interest isn’t expected to dissipate anytime soon. 
Via Talk Markets
Exposures COVID-19
Early JW Therapeutics Backer Ruins Regulatory Breakthrough Party With Stake Sale
Key takeaways: • Less than two weeks after JW Therapeutics received regulatory approval to commercialize its core product in China, key early... 
Via Benzinga
4 Stocks Insiders Are Selling
When insiders sell shares, it indicates their concern in the company’s prospects or that they view the stock as being overpriced. Either way, this signals an opportunity to... 
Via Benzinga
Investors Cheer Onconova's Rigosertib Combo Data In Lung Cancer Setting
Onconova Therapeutics Inc (NASDAQ: ONTX) has announced preliminary data from Phase 1/2a trial of rigosertib plus Bristol-Myers Squibb Co's (NYSE: BMY) Opdivo (... 
Via Benzinga
Mirati Unveils Long-term Survival Data For Sitravatinib/Nivolumab Combo In Lung Cancer Patients
Mirati Therapeutics Inc (NASDAQ: MRTX) has announced results from a post hoc exploratory analysis of the Phase 2 study, MRTX-500 of sitravatinib combined... 
Via Benzinga
The Week Ahead In Biotech (Sept. 19-25): Incyte, Verrica FDA Decisions And Conference Presentations In The Spotlight
Biotech stocks declined for the week ending Sept. 17, extending the losses from the previous week. European Society for Medical Oncology presentations, vaccine news, clinical... 
Via Benzinga
Exposures Product Safety
Visualizing the World’s Biggest Pharmaceutical Companies
Some of the world’s biggest pharmaceutical companies have played a central role in the COVID-19 pandemic. 
Via Talk Markets
Exposures COVID-19
Gritstone Unveils "Off-The-Shelf" Neoantigen Immunotherapy Data In Lung Cancer
Gritstone bio Inc (NASDAQ: GRTS) has announced results with its SLATE v1 product ("off-the-shelf" shared neoantigen immunotherapy). The therapy is in... 
Via Benzinga
Gritstone Presents Data From Individualized Neoantigen Immunotherapy In Colorectal Cancer
Gritstone bio Inc (NASDAQ: GRTS) has announced updated results from the Phase 1/2 study of GRANITE individualized neoantigen immunotherapy in advanced solid tumors... 
Via Benzinga
These Industries Stand To Benefit From The Infrastructure Bill — And These Companies Are Lobbying Against It
The Biden administration is attempting to reshape the American economy by adding more stimulus bills both to create jobs, bolster infrastructure, adapt to a changing climate and... 
Via Benzinga
Topics Economy
Exposures Economy
Bristol Myers Touts 5-Year Kidney Cancer Data For Opdivo-Yervoy Combo Therapy
Bristol Myers Squibb Co (NYSE: BMY) announced Opdivo (nivolumab) plus Yervoy (ipilimumab) long-term survival data in patients with previously untreated advanced or... 
Via Benzinga
8 Health Care Stocks With Unusual Options Alerts In Today's Session
This unusual options alert can help traders track potentially big trading opportunities. Traders often look for circumstances when the market estimation of an option diverges away... 
Via Benzinga
Exelixis' Cabometyx Combo Trial Shows Benefit In Kidney Cancer Regardless Of Prior Surgery
Exelixis Inc (NASDAQ: EXEL) has announced results demonstrating efficacy benefits of Cabometyx (cabozantinib) in patients with previously untreated advanced renal... 
Via Benzinga
Investing in These 2 Top Stocks Could Make You Richer Over the Next 10 Years
Don't miss out on these two thriving businesses. 
Via The Motley Fool
Pressure Day
Today a recovery came to markets with a particular impact on uranium shares. 
Via Talk Markets
Bristol Myers' Immunotherapy Combo Shows Durable Survival At Three Years In MPM Setting
Bristol Myers Squibb & Co (NYSE: BMY) announced three-year data from the CheckMate -743 trial demonstrating a durable survival benefit with first-line... 
Via Benzinga
< Previous 1 2
...
25 26 27 28 29 30 31 32 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.